Gilead's Yescarta beats estimates

In its 2Q18 earnings released Wednesday, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the

Read the full 325 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE